Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New Haven, Connecticut.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -72.10% |
| Return on Assets | -43.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $19.47 |
| Price-to-Book | 6.60 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $41.78M |
| Float | $32.29M |
| % Insiders | 2.49% |
| % Institutions | 98.49% |
Volatility is currently contracting
Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript
Veradermics NYSE: MANE reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, October 19, 2026, at 8:00 am ET to review results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘304') evaluating VDPHL01, a proprietary, extended-re.
Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Investor Meetings: Tuesday, September 8, 2026 in Boston, MA Citi's 2026 Biopharma Back to School Conference Presentation: Wednesd.
MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during th.
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from its open-label Phase 2 clinical trial (Study ‘207') evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss. VDPHL01 has the potential to become the first FDA-approved oral.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MANE and any ticker you trade — then tracks every position and per-strategy win rate.
